Tags Archive Navigation
icon
-
Media ReleaseAveXis Enters into Licensing Agreement with Genethon
-
Media ReleaseAveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)
-
Media ReleaseAveXis Reports First Quarter 2018 Financial and Operating Results
-
Media ReleaseAveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
-
Media ReleaseAveXis Community Statement on the Global Managed Access Program for AVXS-101
-
Media ReleaseAveXis Community Statement on the Coronavirus Disease (COVID-19)
-
Media ReleaseAveXis Community Statement on Global Managed Access Program for AVXS-101
-
Media ReleaseAveXis Statement on Changes to Senior Leadership Team
-
Media ReleaseNovartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
-
Media ReleaseNovartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
-
Media ReleaseNovartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
-
Media ReleaseNovartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
Pagination
- ‹ Previous page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- …
- 32
- › Next page